NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Price Target & More

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) posted its earnings results on Tuesday, May, 8th. The biotechnology company reported $0.61 earnings per share for the quarter, beating analysts' consensus estimates of $0.53 by $0.08. The biotechnology company earned $44 million during the quarter, compared to analyst estimates of $40.77 million. Enanta Pharmaceuticals had a net margin of 31.60% and a return on equity of 18.50%. Enanta Pharmaceuticals's revenue for the quarter was up 388.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.28) earnings per share. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Enanta Pharmaceuticals.

6 brokers have issued 1-year price objectives for Enanta Pharmaceuticals' stock. Their forecasts range from $36.00 to $135.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $79.1667 in the next year. View Analyst Ratings for Enanta Pharmaceuticals.

Some companies that are related to Enanta Pharmaceuticals include Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO), FibroGen (FGEN), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Taro Pharmaceutical Industries (TARO) and Ligand Pharmaceuticals (LGND).

Press coverage about ENTA stock has trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 0.04 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.97 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Enanta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.34%), Farallon Capital Management LLC (4.75%), Dimensional Fund Advisors LP (3.10%), Franklin Resources Inc. (1.49%), Matarin Capital Management LLC (1.17%) and Prudential Financial Inc. (1.13%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Franklin Resources Inc., Barclays PLC, Virginia Retirement Systems ET AL, Farallon Capital Management LLC and Northern Trust Corp. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda and Paul J Mellett. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was purchased by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Prudential Financial Inc., Spark Investment Management LLC, California Public Employees Retirement System, Dimensional Fund Advisors LP, Chicago Equity Partners LLC, UBS Group AG and Russell Investments Group Ltd.. View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $119.60.

Enanta Pharmaceuticals has a market capitalization of $2.29 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]